Ipsen Advances Phase III Aesthetics Bet With New IPN10200 Frown-Line Study

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

The Phase III study NCT07435428, run by Ipsen, will test IPN10200 in adults with moderate to severe frown lines between the eyebrows. It aims to show how well a single dose and repeat dosing can smooth these lines over time and how safe the treatment is, a key step before seeking broader aesthetic market use.

IPN10200 is an injectable biological product given into the small muscles that cause frown lines. A placebo injection without active drug is used as a control so researchers can clearly see if IPN10200 adds real benefit.

The trial starts with a double-blind phase, where people are randomly assigned to IPN10200 or placebo and neither patients nor study staff know who gets what. It then moves to an open-label phase where all eligible participants receive IPN10200, allowing longer term tracking of effect and safety.

This is a randomized, parallel-group design with four levels of masking in the first phase, focused on treatment rather than prevention. Such a setup is standard for late-stage aesthetic drugs and is meant to give clear, objective data that regulators and payers can trust.

The study was first submitted on 17 February 2026, signaling Ipsen’s push to expand its aesthetics pipeline. The latest update on 25 February 2026 confirms the protocol details and shows the company is preparing to move from planning into active execution.

Status is “not yet recruiting,” so no primary or final completion dates are posted and no results are available yet. Investors should view this as an early but important milestone, with value creation tied to future enrollment progress and eventual readouts.

For Ipsen (GB:0MH6), this program targets a large, cash-generative market now led by AbbVie’s Botox and competitors such as Galderma and Revance. If IPN10200 shows strong, long-lasting effects with a clean safety profile, it could support a higher growth narrative in aesthetics and diversify revenue beyond core therapeutic areas.

In the near term, the update is unlikely to move the share price on its own, but it adds depth to Ipsen’s late-stage pipeline and may support sentiment among growth-focused healthcare investors. Any future signs of fast enrollment or positive interim safety updates could become catalysts, especially if peers face setbacks or pricing pressure.

The study remains in the set-up phase and is not yet recruiting, with ongoing updates and further details available on the ClinicalTrials portal.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.